Radical prostatectomy vs. intensity-modulated radiation therapy in the management of localized prostate adenocarcinoma

Radiotherapy and Oncology

Volumn 93, Issue 2, 2009, Pages 185-191

  Aizer, Ayal A ^a   Yu, James B ^a   Colberg, John W ^a   McKeon, Anne M ^a   Decker, Roy H ^a   Peschel, Richard E ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biochemical; Cancer; Outcome; Prostate; Radiation; Surgery

Indexed keywords

GONADORELIN AGONIST; HORMONE RECEPTOR BLOCKING AGENT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE FREE INTERVAL; GLEASON SCORE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RETROSPECTIVE STUDY; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADENOCARCINOMA; ADULT; AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES;

EID: 70350515452     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.09.001     Document Type: Article

References (37)

1. Peschel R.E., and Colberg J.W. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 4 (2003) 233-241
2. Paulson D.F., Lin G.H., Hinshaw W., and Stephani S. Radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 128 (1982) 502-504
3. Hanks G.E. More on the Uro-Oncology Research Group report of radical surgery vs. radiotherapy for adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 14 (1988) 1053-1054
4. Repetto L., Granetto C., and Hall R.R. Prostate cancer. Crit Rev Oncol Hematol 27 (1998) 145-146
5. Byhardt R.W., Greenlaw R.H., Jensen R., et al. Re: radical surgery versus radiotherapy for adenocarcinoma of the prostate. J Urol 130 (1983) 1205-1206
6. Keyser D., Kupelian P.A., Zippe C.D., Levin H.S., and Klein E.A. Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or =10 ng/ml: radiation therapy or surgery?. Int J Radiat Oncol Biol Phys 38 (1997) 723-729
7. D'Amico A.V., Whittington R., Kaplan I., et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4-20 ng/ml. Int J Radiat Oncol Biol Phys 37 (1997) 1053-1058
8. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
9. Martinez A.A., Gonzalez J.A., Chung A.K., et al. A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution. Cancer 88 (2000) 425-432
10. Kupelian P.A., Elshaikh M., Reddy C.A., Zippe C., and Klein E.A. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol 20 (2002) 3376-3385
11. Kupelian P.A., Potters L., Khuntia D., et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 25-33
12. Potters L., Klein E.A., Kattan M.W., et al. Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71 (2004) 29-33
13. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era. Cancer 95 (2002) 281-286
14. Cahlon O., Hunt M., and Zelefsky M.J. Intensity-modulated radiation therapy: supportive data for prostate cancer. Semin Radiat Oncol 18 (2008) 48-57
15. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
16. Zelefsky M.J., Chan H., Hunt M., Yamada Y., Shippy A.M., and Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176 (2006) 1415-1419
17. D'Amico A.V., Chen M.H., Renshaw A.A., Loffredo M., and Kantoff P.W. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 299 (2008) 289-295
18. D'Amico A.V., Manola J., Loffredo M., Renshaw A.A., DellaCroce A., and Kantoff P.W. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292 (2004) 821-827
19. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
20. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360 (2002) 103-106
21. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50 (2001) 1243-1252
22. Roach III M., Bae K., Speight J., et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol 26 (2008) 585-591
23. Pilepich M.V., Winter K., Lawton C.A., et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys 61 (2005) 1285-1290
24. Thames H., Kuban D., Levy L., et al. Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 57 (2003) 929-943
25. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
26. Cookson M.S., Aus G., Burnett A.L., et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177 (2007) 540-545
27. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.
28. Zelefsky M.J., Hollister T., Raben A., Matthews S., and Wallner K.E. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 47 (2000) 1261-1266
29. Zelefsky M.J., Wallner K.E., Ling C.C., et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J Clin Oncol 17 (1999) 517-522
30. Gilbert E.H., Lowenstein S.R., Koziol-McLain J., Barta D.C., and Steiner J. Chart reviews in emergency medicine research: where are the methods?. Ann Emerg Med 27 (1996) 305-308
31. Klein J.P., Logan B., Harhoff M., and Andersen P.K. Analyzing survival curves at a fixed point in time. Stat Med 26 (2007) 4505-4519
32. Kattan M.W., Eastham J.A., Stapleton A.M., Wheeler T.M., and Scardino P.T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766-771
33. Frank S.J., Levy L.B., Kuban D.A., et al. Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M.D. Anderson Cancer Center experience with (125)iodine brachytherapy. J Urol 181 (2009) 1658-1663 [discussion 1663-1654]
34. Kuban D.A., Thames H.D., Levy L.B., et al. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 57 (2003) 915-928
35. Kattan M.W., Zelefsky M.J., Kupelian P.A., Scardino P.T., Fuks Z., and Leibel S.A. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18 (2000) 3352-3359
36. Pollack A., Zagars G.K., Smith L.G., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18 (2000) 3904-3911
37. Nielsen M.E., Makarov D.V., Humphreys E., Mangold L., Partin A.W., and Walsh P.C. Is it possible to compare PSA recurrence-free survival after surgery and radiotherapy using revised ASTRO criterion - "nadir + 2"?. Urology 72 (2008) 389-393 [discussion 394-385]